Celgene Co. (CELG) Shares Bought by Davidson & Garrard Inc.
Davidson & Garrard Inc. increased its holdings in shares of Celgene Co. (NASDAQ:CELG) by 6.3% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned 12,333 shares of the biopharmaceutical company’s stock after purchasing an additional 730 shares during the period. Davidson & Garrard Inc.’s holdings in Celgene were worth $1,798,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also bought and sold shares of the stock. BlackRock Inc. lifted its position in shares of Celgene by 5.7% during the 2nd quarter. BlackRock Inc. now owns 56,725,342 shares of the biopharmaceutical company’s stock worth $7,366,919,000 after purchasing an additional 3,084,227 shares during the last quarter. Vanguard Group Inc. raised its holdings in Celgene by 3.1% in the 2nd quarter. Vanguard Group Inc. now owns 53,527,210 shares of the biopharmaceutical company’s stock valued at $6,951,579,000 after acquiring an additional 1,610,056 shares in the last quarter. Jennison Associates LLC raised its holdings in Celgene by 11.5% in the 3rd quarter. Jennison Associates LLC now owns 14,962,407 shares of the biopharmaceutical company’s stock valued at $2,181,818,000 after acquiring an additional 1,546,673 shares in the last quarter. FMR LLC raised its holdings in Celgene by 5.9% in the 2nd quarter. FMR LLC now owns 12,594,467 shares of the biopharmaceutical company’s stock valued at $1,635,643,000 after acquiring an additional 697,250 shares in the last quarter. Finally, Franklin Resources Inc. raised its holdings in Celgene by 3.3% in the 2nd quarter. Franklin Resources Inc. now owns 11,080,093 shares of the biopharmaceutical company’s stock valued at $1,439,025,000 after acquiring an additional 349,974 shares in the last quarter. 79.74% of the stock is owned by institutional investors and hedge funds.
Several research firms have commented on CELG. UBS Group cut Celgene from a “strong-buy” rating to a “market perform” rating and set a $160.00 price target for the company. in a report on Thursday, October 26th. BMO Capital Markets cut their price target on Celgene from $163.00 to $148.00 and set an “outperform” rating for the company in a report on Friday, October 27th. Robert W. Baird cut Celgene from an “outperform” rating to a “neutral” rating and cut their price target for the company from $162.00 to $136.00 in a report on Friday, October 20th. BTIG Research reaffirmed a “hold” rating on shares of Celgene in a report on Sunday, October 22nd. Finally, Vetr raised Celgene from a “buy” rating to a “strong-buy” rating and set a $144.39 price target for the company in a report on Monday, October 23rd. One research analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and nineteen have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $131.18.
Shares of Celgene Co. (NASDAQ CELG) opened at $106.00 on Monday. Celgene Co. has a 12 month low of $94.55 and a 12 month high of $147.17. The firm has a market capitalization of $83,460.00, a P/E ratio of 25.00, a PEG ratio of 0.68 and a beta of 1.77. The company has a quick ratio of 3.52, a current ratio of 3.65 and a debt-to-equity ratio of 1.31.
Celgene (NASDAQ:CELG) last released its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.91 EPS for the quarter, topping the Zacks’ consensus estimate of $1.87 by $0.04. The business had revenue of $3.29 billion for the quarter, compared to analyst estimates of $3.42 billion. Celgene had a return on equity of 63.80% and a net margin of 27.36%. Celgene’s revenue for the quarter was up 10.2% on a year-over-year basis. During the same period in the prior year, the company earned $1.58 EPS. sell-side analysts predict that Celgene Co. will post 6.69 earnings per share for the current year.
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with Analyst Ratings Network's FREE daily email newsletter.